AKTX.US Akari Therapeutics PLC

Healthcare Pharmaceuticals USA Stocks
6.94 USD
Close of Nov 13, 2026
3.02 29.32
Market cap
USD 15.9M
P/E
-
P/B
0.82x
ROE
-183.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is AKTX.US undervalued?

Graham number

The Graham number of Akari Therapeutics PLC cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Akari Therapeutics PLC fundamental analysis

No fundamental analysis for Akari Therapeutics PLC yet.

Akari Therapeutics PLC stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Akari Therapeutics PLC

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric…

Full company profile